Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study on Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment Associated With CSVD
Sponsor: Beijing Tiantan Hospital
Summary
This study aimed to explore the efficacy and safety of Ginkgo Biolba Extract fifty in treating mild cognitive impairment associated with cerebral small vessel disease (CSVD). Subjects included based on eligibility criteria were randomized into treatment and control groups. Patients will receive the drug or placebo for 12 months. Patients were followed at baseline and at 3 months, 6 months, and 12 months after randomization. The primary outcome was the difference from baseline in the Montreal Cognitive Assessmen (MoCA) score at 12 months after randomization.
Official title: Study on Ginkgo Biolba Extract Fifty in the Treatment of Mild Cognitive Impairment Associated With Cerebral Small Vessel Disease
Key Details
Gender
All
Age Range
50 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
144
Start Date
2024-09-01
Completion Date
2026-06-30
Last Updated
2024-08-28
Healthy Volunteers
No
Conditions
Interventions
Ginkgo biloba extract 50 dropping pills
Composition: Ginkgo ketone ester, excipient polyethylene glycol 6000. Size: 10mg ginkgolides/pill.
Ginkgo biloba extract Ginkgo biloba extract 50 Drops simulant
Composition: The main ingredient is polyethylene glycol 6000 + caramel pigment, placebo and ginkgolide drops are basically the same in color, odor and appearance. Size: 10 mg analog ingredient/pill.